FCA blames political conditions in France for failed Renault merger - Breaking The News
Download our appPlay StoreApp Store

FCA blames political conditions in France for failed Renault merger

EPA-EFE / MAURITZ ANTIN

Fiat Chrysler Automobiles N.V. (FCA) confirmed on Thursday that it ended merger talks with Groupe Renault with immediate effect. In spite of reports claiming that the negotiations failed because Renault board members from Nissan Motor Co. withdrew their support, FCA thanked them "for their constructive engagement on all aspects" of the proposal.

"FCA remains firmly convinced of the compelling, transformational rationale of a proposal that has been widely appreciated since it was submitted, the structure and terms of which were carefully balanced to deliver substantial benefits to all parties. However it has become clear that the political conditions in France do not currently exist for such a combination to proceed successfully," the company stated.

Related Stocks
FIAT CHRYSLER AUT...
Renault
Related News
Musk's xAI acquires social media platform X
Billionaire entrepreneur Elon Musk announced on Friday that X.AI Corp. (doing business as xAI) acquired the social media platform X in an all-stock transaction."xAI and X’s futures are intertwined. Today, we officially take the step to combine the data, models, compute, distribution and talent. This combination will unlock immense potential by blending xAI’s advanced AI capability and expertise with X’s massive reach. The combined company will...
Repsol UK to form new unit with NEO Energy
Spanish petrochemical company Repsol S.A. announced on Thursday that its British business will combine with NEO Energy Group's North Sea arm to form Neo Next Energy. The resulting unit will be managed by a joint team, with NEO owning 55% and Repsol 45%."This combination will create a jointly governed business which will call upon the key strengths of both shareholders," Repsol Exploration and Production Executive Managing Director Francisco Gea said....
Merck to buy Hengrui Pharma's drug for up to $1.8B
Merck & Co. Inc. said on Tuesday that it entered into an exclusive license agreement with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for a cardiovascular disease drug HRS-5346, currently in a phase 2 trial in China. Merck will pay $200 million upfront and commit to milestone payments of up to $1.8 billion, as well as royalties on net sales.The drug is an investigational oral small molecule inhibitor of lipoprotein(a) formation (lp(a)). "Elevated blood concentrations of...
UK regulator aims to boost market trust, encourage risk
Britain's Financial Conduct Authority (FCA) is pushing for savers to take more financial risks as part of a new five-year strategy aimed at addressing challenges linked to an aging population, the Financial Times reported, citing FCA Chair Ashley Alder. The regulator also seeks to strengthen trust in financial markets by stepping up efforts to combat fraud. Alder said the FCA would back government plans to ease regulatory burdens and drive economic growth by...

Please observe our Terms of Use. The price information is time delayed to varying extents, but as a rule by 15 minutes or more, according to the regulations of the selected stock exchange and/or licensors and the type of securities.

© 2025 TeleTrader Software GmbH. All rights reserved

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.